PHILADELPHIA - A benign virus normally found in the skin can lead to a type of rare, lethal skin cancer. Specifically, infection by the Merkel cell polyomavirus can lead to Merkel cell carcinoma in immune-compromised individuals. Researchers have now identified a type of skin cell as the target of the virus in humans. This study, from the Perelman School of Medicine at the University of Pennsylvania, establishes a new way to investigate this type of oncogenic viral infection and identifies a potential therapeutic agent against Merkel cell polyomavirus infection.
Merkel cell carcinoma, which metastasizes rapidly, is one of the most aggressive skin cancers, with a mortality rate of 33 percent, exceeding that of melanoma, and a 45 percent five-year survival rate. Given these dire statistics, researchers are keen to find better treatments.
Senior author Jianxin You, PhD, an associate professor of Microbiology, published her results this month in Cell Host & Microbe. "We established a cell culture model for Merkel cell polyomavirus infection, which will help us find how this DNA virus causes cancer," You said.
Using this model, the team discovered that the activation of special enzymes called matrix metalloproteinases by a cellular signaling pathway involving the WNT and ?-catenin proteins stimulate Merkel cell polyomavirus infection. "This suggests that Merkel cell carcinoma risk factors such as ultraviolet radiation and aging, which are known to stimulate the expression of these metalloproteinase enzymes, may promote viral infection and thus drive the development of cancer."
These enzymes work in wound healing to re-engineer the skin as it heals. For example, if the skin is harmed by excessive sunlight, this stimulates the WNT/β-catenin signaling pathway, which in turn activates the metalloproteinase enzymes to be made. In the wound-healing process, these enzymes "chew up" the extracellular matrix of affected cells. This could allow viruses to enter the cells of the dermis skin layer, surmise the researchers.
The Merkel cell polyomavirus is an abundant virus frequently found on healthy human skin. Excessive exposure to sunlight and ultraviolet radiation, immune suppression, and advanced age are the most important risk factors for Merkel cell carcinoma. Although the exact function of Merkel cells, found in the lower part of the skin epidermis, is unknown, they are thought to be nerve-associated cells involved in light touch sensation.
This study also found that the FDA-approved drug trametinib for melanoma and other cancers blocks viral infection by stopping Merkel cell polyomavirus transcription and replication. Low doses of trametinib wiped out viral infection in the cell culture model developed by first author Wei Liu, PhD, a senior postdoctoral fellow in the You laboratory. In addition, normal control cells were not affected e trametinib, giving hope to the fact that this drug might be able to be used with little side effects for reducing the viral load in immunocompromised patients and the goal of preventing the development of Merkel cell carcinoma.
"Building on this novel cell culture model for Merkel cell polyomavirus infection, we would like to establish an animal model to elucidate the mechanisms by which Merkel cell polyomavirus infection leads to the highly aggressive Merkel cell carcinoma," Liu said.
This work built on the system for production of both Merkel cell polyomavirus pseudovirus and recombinant virions established in the laboratory of Christopher B. Buck, PhD at the National Cancer Institute.
###
Aimee S. Payne and Xiao Xiaowei (George) Xu, bot h from Penn were also co-authiors.
This work was supported by the National Institutes of Health (R01CA148768, R01CA142723, R01CA187718, NIAMS AR064220, R01AR054593, P50CA174523), the Intramural Research Program of the NIH, and the Center for Cancer Research.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.
Journal
Cell Host & Microbe